Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2011

View Archived Issues

Scientists use Ppp1r15a promoter to develop constructs for tumor-specific imaging

Novo Nordisk reviews highlights fourth quarter 2010

Initial doses of TRC-105 are tolerated in patients with castration-resistant prostate cancer

Promising phase II data on cabozantinib in patients with prostate cancer and soft tissue disease

Quest Diagnostics' proprietary EGF-SERS nanoparticles detect circulating tumor cells in whole blood

Tasquinimod improves PFS in phase II trial in metastatic CRPC

Corticotropin-releasing factor receptor antagonist astressin B activates hair growth in vivo

Prima BioMed receives scientific advice from EMA on CVac trial

EMA committee recommends approval of Sprimeo HCT for hypertension

CHMP recommends change to Humira indication

FDA requires boxed warning for terbutaline for preterm labor

Bayer presents new progesterone receptor antagonists

Novavax reports phase II data on its H1N1 VLP pandemic influenza vaccine

Pharming initiates phase IIIb Rhucin trial in acute hereditary angioedema

Verona Pharma completes trial of RPL-554 in patients with mild asthma

Medivir reports interim data from phase IIb PILLAR trial of TMC-435 in HCV infection

Otuska Pharma's WT1 mRNA assay kit approved for additional use in Japan

Boston Scientific launches Promus and Taxus stent systems in India

MorphoSys receives milestone payment from Novartis in connection with HuCAL technology

Merck Frosst discloses new acyl-CoA desaturase inhibitors

Chelsea Therapeutics prices public offering

Novel histamine receptor modulators presented by Medivation

Eisai reports novel inhibitors of beta-amyloid production

Takeda begins voluntary recall of Dasen in Japan

Merck presents new SCD1 inhibitors for metabolic and other disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...